We are so proud to be FIRST IN THE REGION to offer a new PSMA imaging agent for prostate cancer.
According to the American Cancer Society, 1 in 8 men will be diagnosed with prostate cancer during their lifetime with 268,490 new cases of prostate cancer forecasted for 2022 and approximately 34,500 deaths. As with any cancer, early detection is key to decreased morbidity, improved quality of life, and survivorship. At West, our Radiology department remains on the forefront for not only cancer detection but the latest advances in treatment.
At West Cancer Center, detection and staging of prostate cancer has expanded beyond conventional means with a new, FDA-approved, prostate-specific PET/CT using a radiopharmaceutical called PSMA that has a much wider indication for all stages of prostate cancer and has fewer payer restrictions.
Hartwell Strain, our Radiology Department Director, met with Gina Neely on WREG News Channel 3‘s Bluff City Life about new advancements for men with and at risk for developing prostate cancer. Click the video below to watch the full interview!
